Medkonsta, MB

Company age: 8 y. 7 mo.

Update

Company overview

Company name Medkonsta, MB
Company code 304777490
VAT code LT100017546117
Registered address Širvintų r. sav., Širvintų sen., Puorių k., Vasaros g. 15, LT-19134
Registration date 2018-02-26 Company age: 8 y. 7 mo.
Phone Phone
Email Email
Company manager For registered members only Log in
Revenue (2025) 32,869 € +25% History
Profit (2025) 4,341 € -67% History
Number of employees 0
Managed vehicles 4 List
Current SODRA debt No debt Read more
Days of debt to SODRA per year 0 days
Current VMI debt No debt Read more
Financial statements All submitted
Legal form Small partnership
NACE activity New construction
Ownership form Private without foreign capital
Managed brands 1 List

Download a detailed company report

Make confident decisions with all the information about Medkonsta, MB. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.

19.99 € + PVM Get report

Description

This description was generated by artificial intelligence.
Medkonsta, MB (company code 304777490) is an operational private small partnership registered in 2018. It belongs to the sector of national private non-financial companies and is owned through private Lithuanian ownership, with more than 50% of authorised capital held by Lithuanian natural and legal persons and no foreign investor capital. The company is governed by a CEO only and is classified as a micro company. Its activity is listed under EVRK code F.41.00.10, New construction. The registered address is Vasaros g. 15, Puoriu k., Širvintu sen., Širvintu r. sav., Vilniaus apskr., Lithuania. Financially, the company increased revenue from €19.1K in 2023 to €26.3K in 2024 and €32.9K in 2025, which corresponds to 24.8% year-on-year growth in the latest year and 71.9% growth over two years. Net profit was €7.5K in 2023, €13.3K in 2024 and €4.3K in 2025, with the latest profit margin at 13.2%. At year-end 2025, equity stood at €22.3K and total assets at €22.7K, with liabilities of €370 and a high equity ratio of 98.4%.